FDA Approves Rexulti For Agitation Associated With Dementia Due To Alzheimer's

The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.
The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.

Pyrls on Instagram: Brexpiprazole's (REXULTI) new indication makes it the first FDA-approved option for agitation associated with dementia due to Alzheimer's disease ✨ Learn more about brexpiprazole in your Pyrls app or

Decision on Brexpiprazole for Alzheimer's Agitation Due in May

Researcher finds help for Alzheimer's-associated agitation with new FDA- approved treatment

FDA Approves First Drug to Treat Dementia-Associated Agitation in AD Patients

FDA Approves Rexulti For Agitation Associated With Dementia Due To Alzheimer's

Dementia: FDA fast-tracks approval for antipsychotic drug Rexulti

Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA Approval For Alzheimer's Agitation

What is agitation that may happen with dementia due to Alzheimer's disease?

FDA approves first drug to treat agitation associated with dementia due to Alzheimer's

Rexulti Shows Efficacy Treating Agitation Associated With Dementia Due to Alzheimer Disease

FDA approves treatment for agitation associated with dementia created by Princeton-based Otsuka

Leqembi Granted Full FDA Approval to Treat Early Alzheimer's Disease

Brexpiprazole Demonstrates Clinically Meaningful Improvements for Agitation Due to Alzheimer Disease